Evommune company information, Employees & Contact Information

Evommune Announces Late-Breaker Presentation of Phase 2 Data for EVO756 in Chronic Inducible Urticaria at Upcoming European Academy of Dermatology and Venereology (EADV) 2025 Congress PR Newswire

Inflammation biotech Evommune eyes IPO to fund dermatitis trials Fierce Biotech

Evommune files for IPO to advance immune drug work BioPharma Dive

Evommune Aims For IPO In Bifurcated Biopharma Market (Pending: EVMN) Seeking Alpha

Evommune Launches Phase 2b Trial of Oral MRGPRX2 Antagonist, EVO756, In Adults With Atopic Dermatitis Patient Care Online

Evommune Advances EVO756 Into Global Phase 2b Trial for Chronic Spontaneous Urticaria Dermatology Times

Evommune to Participate in Three Upcoming Investor Conferences PR Newswire

Evommune starts second midstage clinical trial this year The Business Journals

EVMN IPO News - Chronic inflammatory disease biotech Evommune files for a $100 million IPO renaissancecapital.com

Evommune enrols first subject in chronic inducible urticaria therapy trial Clinical Trials Arena

Evommune raises $115M to accelerate immune drug tests BioPharma Dive

Exploring EVO756 in Chronic Inflammatory Disease Treatment: Q&A with Evommune's Mark Jackson, MD Dermatology Times

EVMN IPO News - Chronic inflammatory disease biotech Evommune sets terms for $150 million IPO renaissancecapital.com

Evommune Closes $50 Million Series B Financing to Advance Broad Pipeline of Therapies to Treat Chronic Inflammatory Diseases PR Newswire

Phase 2 Trial Begins for EVO756 in Chronic Inducible Urticaria Dermatology Times

Evommune and Accutar Biotechnology Announce AI Drug Discovery Collaboration PR Newswire

Evommune Adds Additional Investment In Series B Financing And Bolsters Leadership Team PR Newswire

Evommune Secures Exclusive Rights to Develop and Commercialize a Phase 2-ready IL-18 targeted fusion protein from AprilBio PR Newswire

Evommune Announces Appointment of Kyle Carver as Chief Financial Officer PR Newswire

Evommune Inc., Completes $83 Million Series A Financing to Advance Development of Unique Chronic Inflammation Pipeline PR Newswire

Evommune files for proposed NYSE IPO Investing.com

Evommune files for IPO on NYSE under symbol EVMN Investing.com

Peninsula biotech Evommune puts skin in IPO game - San Francisco Business Times The Business Journals

Evommune begins Phase I trial of EVO756 for spontaneous urticaria Clinical Trials Arena

Evommune and Axcelead Drug Discovery Partners Launch A Collaboration On A PKC[theta] Program To Kick-off Evommune's Inflammation Pipeline PR Newswire

Evommune targets $159M raise in IPO Axios

Evommune announces completion of $50 million Series B financing Healio

Evommune In-Licenses Three Development Programs Focused on Treating Inflammatory Conditions from Dermira, a Wholly-Owned Subsidiary of Eli Lilly and Company PR Newswire

New PKCθ inhibitors disclosed in Evommune patent BioWorld MedTech

Evommune drops IRAK4 inhibitor after assessing phase 2 dermatitis data Fierce Biotech

Evommune IPO: everything you need to know Capital.com

Evommune’s Human Tissue-based Approach Enables Discovery and Development of Safer, Innovative Chronic Inflammation Therapies BioSpace

Evommune’s unique method of drug discovery is more than skin deep Pharma Voice

Aprilbio, Evommune strike $475M deal for autoinflammatory drug BioWorld MedTech

Evommune, Biotech Focused on Inflammatory Diseases, Files for IPO MarketScreener

Inflammation-focused Evommune raises $50M amid the Series B blues The Business Journals

Evommune and Accutar Collaborate on AI-based Drug Discovery Genetic Engineering and Biotechnology News

Ex-Dermira founders pick up $83M for Evommune to advance programs in-licensed from Lilly's Dermira Fierce Biotech

First Look | Evommune (Pending:EVMN) Seeking Alpha

Evommune Inc. (EVMN): Peeking at the IPO Prospectus of a Chronic Inflammatory Biotech Company Smartkarma

Evommune Inc. (EVMN): Chronic Inflammatory Biotech Sets Terms Seeking up to $511m Valuation Smartkarma

Evommune in-licenses assets from Lilly's Dermira The Pharma Letter

Peninsula drug startup 'team that has done it all' lands $83M funding The Business Journals

Evommune (EVMN) to Raise $150.40 million in IPO Defense World